Most of the mainstream media is still laser-focused on the post-election turmoil and whether or not President Donald Trump will concede in the wake of the media declaring Democratic nominee Joe Biden the president-elect.
In the meantime, Trump has been scoring victories on a front that has a direct effect on American lives. Thanks to the president’s leadership in the fight against COVID-19, biotechnology company Moderna Inc. announced its vaccine tests resulted in a staggering 94.5% effectiveness, PJ Media reported.
The welcoming news came on the heels of drug maker Pfizer announcing similar good news, claiming its COVID-19 vaccine tests resulted in a 90% effective rate.
Thanks to the president’s swift creation of “Operation Warp Speed,” drug companies were bolstered by the resources of the U.S. government in their attempt to accelerate the production of an effective vaccine against the global pandemic.
Moderna CEO Stéphane Bancel acknowledged the program in a statement announcing her company’s success in creating a vaccine in such a short time period.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” Bancel said. “I want to thank our partners at BARDA and Operation Warp Speed who have been instrumental to accelerating our progress to this point.”
Bancel explained that the crucial phase three tests during the creation of the vaccine, which included a staggering 30,000 volunteers, gave the company confidence that its vaccine can even treat those with “severe” cases of the virus.
Adding to Moderna’s success is the fact that, unlike Pfizer’s version of the vaccine which has to be stored at -94 degrees Fahrenheit and only lasts five days in regular refrigerator temperatures, Moderna’s version is stable at regular refrigerator temperatures for 30 days, PJ Media reported. It can also be stored for up to six months in a -4 degrees Fahrenheit environment.
When is it coming?
Early on during the COVID-19 pandemic, many so-called “experts” and plenty of Trump’s critics in Congress scoffed at the notion of vaccine development and distribution in under a year — an idea that Trump promoted and pledged early on.
While there is still testing to be done by both companies — and any other companies that are expected to develop vaccines — The New York Times indicated that Moderna will have 20 million doses ready by the end of 2020, with Pfizer claiming it have 50 million doses ready at the same time.
While the distribution will likely begin to take place for the masses in early 2021, some COVID-19 patients — those who are at high risk or in critical shape as a result of the disease — could be granted special-use authorization before the end of 2020, according to The Times.
Beyond that, the U.S. government will purchase tens of millions of doses from both companies and distribute them through a Trump-led partnership with some of the country’s largest pharmacy chains, including CVS and Walgreens.